Latest news with #Lapetus
Business Wire
4 days ago
- Business
- Business Wire
Securities Fraud Investigation Into Abacus Global Management, Inc. (ABL) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Abacus Global Management, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ABACUS GLOBAL MANAGEMENT, INC. (ABL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 4, 2025, Morpheus Research published a report alleging, among other things, that Abacus uses fraudulent life expectancy data to drive revenues. Specifically, the report alleges 'contrary to Abacus' disclosures to the SEC' Abacus relies heavily on life expectancy ('LE') reports generated by 'AI powered' Lapetus Solutions. The report states former Abacus employees revealed the Company 'built Lapetus LEs into… the proprietary pricing tool that Abacus made' and 'would not gather the other life expectancy info.' The report asserts 'Abacus' reliance on Lapetus to value its portfolio presents a material risk to the $446 million in claimed life settlements on its books as of Q1 2025' because '[t]he indicative value on a Lapetus LE is 50% higher than with the other LE providers.' On this news, Abacus's stock price fell $1.64, or 21.5%, to close at $6.00 per share on June 4, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Abacus should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
07-05-2025
- Health
- Yahoo
Lapetus Launches Physician-Led Debit-Credit Life Expectancy Report at No Additional Cost
CHARLOTTE, N.C., May 07, 2025--(BUSINESS WIRE)--Lapetus Solutions is introducing a new Debit-Credit based Life Expectancy (LE) Report—a physician-led, and algorithm-based assessment that aligns with established market practices while leveraging Lapetus' core strengths—its clinical expertise and deep understanding of mortality and aging. This rules-based system is derived from survival outcomes documented in the medical and scientific literature. LE estimates are guided by the insured's medical conditions and the physician's expert judgement, capturing the nuances of each case. The Debit-Credit report will be delivered alongside the existing Clinical LE, which remains unchanged, providing clients with two distinct, medically-justified reports in one package. A summary page will highlight key differences and results for easy comparison. Unlike the Clinical LE, which focuses on estimating individual lifespan, the Debit-Credit LE is designed to optimize actual-to-expected (A/E) performance. Back-testing across the full Lapetus database shows the model achieves an A/E ratio exceeding 99%. Availability & Pricing The Debit-Credit LE is currently available at no additional cost beyond the standard Lapetus LE. Initial availability of the combined Clinical and Debit-Credit LE package will be limited. Please reach out to your relationship manager for further details. About Lapetus For over 40 years, Lapetus Solutions has analyzed the survival patterns of over 1 billion individuals, including long-lived insured populations. Backed by tens of thousands of medical studies, Lapetus delivers scientifically grounded insights into how health conditions affect longevity. Scientists at Lapetus pioneered the field of biodemography, which integrates biology with actuarial and demographic sciences to more accurately predict human longevity. Its findings, published in Science, NEJM, and Nature Aging, have shown that many traditional mortality models significantly overestimate survival. With this level of insight and innovation, Lapetus is giving clients the clarity and confidence they need to make more informed decisions. For more information about the Debit-Credit Report, including details on methodology and implementation, please contact Lapetus directly at info@ View source version on Contacts info@
Business Wire
07-05-2025
- Health
- Business Wire
Lapetus Launches Physician-Led Debit-Credit Life Expectancy Report at No Additional Cost
CHARLOTTE, N.C.--(BUSINESS WIRE)--Lapetus Solutions is introducing a new Debit-Credit based Life Expectancy (LE) Report—a physician-led, and algorithm-based assessment that aligns with established market practices while leveraging Lapetus' core strengths—its clinical expertise and deep understanding of mortality and aging. This rules-based system is derived from survival outcomes documented in the medical and scientific literature. LE estimates are guided by the insured's medical conditions and the physician's expert judgement, capturing the nuances of each case. The Debit-Credit report will be delivered alongside the existing Clinical LE, which remains unchanged, providing clients with two distinct, medically-justified reports in one package. A summary page will highlight key differences and results for easy comparison. Unlike the Clinical LE, which focuses on estimating individual lifespan, the Debit-Credit LE is designed to optimize actual-to-expected (A/E) performance. Back-testing across the full Lapetus database shows the model achieves an A/E ratio exceeding 99%. Availability & Pricing The Debit-Credit LE is currently available at no additional cost beyond the standard Lapetus LE. Initial availability of the combined Clinical and Debit-Credit LE package will be limited. Please reach out to your relationship manager for further details. About Lapetus For over 40 years, Lapetus Solutions has analyzed the survival patterns of over 1 billion individuals, including long-lived insured populations. Backed by tens of thousands of medical studies, Lapetus delivers scientifically grounded insights into how health conditions affect longevity. Scientists at Lapetus pioneered the field of biodemography, which integrates biology with actuarial and demographic sciences to more accurately predict human longevity. Its findings, published in Science, NEJM, and Nature Aging, have shown that many traditional mortality models significantly overestimate survival. With this level of insight and innovation, Lapetus is giving clients the clarity and confidence they need to make more informed decisions.
